Single award · contract
Anthim (Obiltoxaximab)
Award ID: 75A50324C00006
FY2024 · complete year · data as of 2026-07-03
A single federal award, with both ends of the trail linked.
$124.5M
Total award value
Award 75A50324C00006 is a contract from the Department of Health and Human Services, $124.5M obligated, FY2024 to FY2029, for Anthim (Obiltoxaximab). The work is performed in New Jersey. It is classified as NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals). Source
Award details
Award typeContract
PIID75A50324C00006
Action date2024
Period56 mo
Awarding agencyDepartment of Health and Human Services →
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNew Jersey →
CategoryNAICS 325412PSC 6505
Competed?Not recordedSource
Total (exact)$124,523,123
More from Department of Health and Human Services
awarded 2025$110.4B
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.